Follow
Tumor Markers
Tumor Marker: a biomarker found in the body system that can be elevated by the presence of all types of cancer. Each tumor marker is indicative of a particular disease process, and are used in oncology to help detect the presence of cancer.
-
OCT 08, 2020 | 10:00 AM
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...SEP 23, 2020 | 10:30 AM
On measuring photons and ions: Impact on panel design, signal detection and data quality 10:30–11:00 am PDT Presented By: Tim Bushnell, PhD, MBA Monitoring immunotherapy with a mass cy...Speaker: Tim Bushnell, PhD, MBA , Gerd Haga Bringeland, MD, PhD , Greg Hopkins, BSPresented at: 9th Annual Fluidigm Mass Cytometry Virtual Summit
SEP 15, 2020 | 8:00 AM
DATE: September 15, 2020 TIME: 08:00am PT Tumorigenesis and cancer progression are affected by the tumor immune microenvironment (TIME). The TIME not only influences the efficiency of existi...JUN 30, 2020 | 9:00 AM
DATE: June 30, 2020 TIME: 9:00am PDT, 12:00pm EDT QC laboratories perform a critical role in demonstrating pharmaceutical products are consistently manufactured, safe, potent, and pure. At t...JUN 30, 2020 | 8:00 AM
DATE: June 30, 2020 TIME: 8:00am PT, 11:00am Understanding the tumor microenvironment (TME) is essential for the development of effective treatments for cancer patients. Traditional multi...JUN 17, 2020 | 1:30 PM
Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...Speaker: Joseph M. Beechem, PhD , Christopher E. Mason, PhD , Robert Schwartz, PhDJUN 16, 2020 | 10:30 AM
...Speaker: Steve Pennington, PhD , Clifford C. Dacso, MD , Arun Sreekumar, PhDPresented at: Agilent's Virtual Mass Spectacular!
JUN 03, 2020 | 4:00 PM
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...Speaker: Anushka Dikshit, PhDJUN 03, 2020 | 12:00 PM
A key step in the clinical production of CAR T cells is the expansion of engineered T cells. To generate enough cells for viable adoptive cell therapy, cells must be robustly stimulated, whi...Speaker: Pratip K. ChattopadhyayJUN 03, 2020 | 9:30 AM
Cancer cells can acquire immune resistance resulting in a loss of immunosurveillance. Tumor cells can upregulate PDL-1 which binds to PD-1. This complex inhibits CD8 Tumor Infiltrating cells...Speaker: Thomas M. Grogan, MDJUN 03, 2020 | 6:00 AM
Immune checkpoint therapies targeting the CTLA-4 and PD-(L)1 pathways have been largely clinically disappointing for patients with prostate cancer. This can be attributed to the highly immun...JUN 03, 2020 | 12:00 AM
Programmed death-1 (PD-1) inhibits T and B cell function upon ligand binding. PD-1 blockade revolutionized cancer treatment, and while numerous patients respond, some develop autoimmune-like...MAY 20, 2020 | 1:15 PM
Background: Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. Despite recent advancements in the treatment of AML, approximately 50% of pat...MAY 20, 2020 | 10:00 AM
The spread of severe acute respiratory syndrome coronavirus 2 (SARS CoV2), changed the daily life of medical oncologists. To keep safe both patients and healthy workers is the most important...Speaker: PLENARY: Paolo Ascierto, MDPresented at: Advancing Science - A Virtual Oncology Conference
MAY 19, 2020 | 1:15 PM
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...MAY 19, 2020 | 12:45 PM
Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset of head and neck squamous cell carcinoma (HNSCC) patients. To identify patient-responders from non-re...MAY 14, 2020 | 3:00 PM
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...MAY 14, 2020 | 3:00 PM
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...MAY 14, 2020 | 2:15 PM
In the past years, next-generation sequencing has revolutionized the way testing is done in the field of clinical oncology research. Parallel testing of genomic markers in tissue biopsies as...MAY 14, 2020 | 2:15 PM
In the past years, next-generation sequencing has revolutionized the way testing is done in the field of clinical oncology research. Parallel testing of genomic markers in tissue biopsies as...MAY 12, 2020 | 9:00 AM
NEW DATE: Date: May 12, 2020 Time: 9:00am PDT, 12:00pm EDT...MAY 08, 2020 | 8:00 AM
DATE: May 8, 2020 TIME: 8:00am PT, 11:00am ET Microsatellite instability (MSI) is the condition of genetic hypermutability that results from impaired DNA mismatch repair (MMR). Studies indic...APR 29, 2020 | 6:00 AM
Background and aim: Multiplexing of biomarker panels by microsphere-based technologies are robust and cost-effective methods. The QuantiGene™ Plex Assay (ThermoFisher Scientific) platf...APR 28, 2020 | 10:00 AM
DATE: April 28, 2020 TIME: 10:00am PT All cells release extracellular vesicles (EVs) that can carry molecular cargo to other cells to affect their function. EVs are promising as potential bi...
OCT 08, 2020 | 10:00 AM
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...
SEP 23, 2020 | 10:30 AM
On measuring photons and ions: Impact on panel design, signal detection and data quality 10:30–11:00 am PDT Presented By: Tim Bushnell, PhD, MBA Monitoring immunotherapy with a mass cy...
Speaker:
Tim Bushnell, PhD, MBA
, Gerd Haga Bringeland, MD, PhD
, Greg Hopkins, BS
Presented at: 9th Annual Fluidigm Mass Cytometry Virtual Summit
SEP 15, 2020 | 8:00 AM
DATE: September 15, 2020 TIME: 08:00am PT Tumorigenesis and cancer progression are affected by the tumor immune microenvironment (TIME). The TIME not only influences the efficiency of existi...
JUN 30, 2020 | 9:00 AM
DATE: June 30, 2020 TIME: 9:00am PDT, 12:00pm EDT QC laboratories perform a critical role in demonstrating pharmaceutical products are consistently manufactured, safe, potent, and pure. At t...
JUN 30, 2020 | 8:00 AM
DATE: June 30, 2020 TIME: 8:00am PT, 11:00am Understanding the tumor microenvironment (TME) is essential for the development of effective treatments for cancer patients. Traditional multi...
JUN 17, 2020 | 1:30 PM
Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
Speaker:
Joseph M. Beechem, PhD
, Christopher E. Mason, PhD
, Robert Schwartz, PhD
JUN 16, 2020 | 10:30 AM
...
Speaker:
Steve Pennington, PhD
, Clifford C. Dacso, MD
, Arun Sreekumar, PhD
Presented at: Agilent's Virtual Mass Spectacular!
JUN 03, 2020 | 4:00 PM
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
Speaker:
Anushka Dikshit, PhD
JUN 03, 2020 | 12:00 PM
A key step in the clinical production of CAR T cells is the expansion of engineered T cells. To generate enough cells for viable adoptive cell therapy, cells must be robustly stimulated, whi...
Speaker:
Pratip K. Chattopadhyay
JUN 03, 2020 | 9:30 AM
Cancer cells can acquire immune resistance resulting in a loss of immunosurveillance. Tumor cells can upregulate PDL-1 which binds to PD-1. This complex inhibits CD8 Tumor Infiltrating cells...
Speaker:
Thomas M. Grogan, MD
JUN 03, 2020 | 6:00 AM
Immune checkpoint therapies targeting the CTLA-4 and PD-(L)1 pathways have been largely clinically disappointing for patients with prostate cancer. This can be attributed to the highly immun...
JUN 03, 2020 | 12:00 AM
Programmed death-1 (PD-1) inhibits T and B cell function upon ligand binding. PD-1 blockade revolutionized cancer treatment, and while numerous patients respond, some develop autoimmune-like...
MAY 20, 2020 | 1:15 PM
Background: Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. Despite recent advancements in the treatment of AML, approximately 50% of pat...
MAY 20, 2020 | 10:00 AM
The spread of severe acute respiratory syndrome coronavirus 2 (SARS CoV2), changed the daily life of medical oncologists. To keep safe both patients and healthy workers is the most important...
Speaker:
PLENARY: Paolo Ascierto, MD
Presented at: Advancing Science - A Virtual Oncology Conference
MAY 19, 2020 | 1:15 PM
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
MAY 19, 2020 | 12:45 PM
Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset of head and neck squamous cell carcinoma (HNSCC) patients. To identify patient-responders from non-re...
MAY 14, 2020 | 3:00 PM
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
MAY 14, 2020 | 3:00 PM
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
MAY 14, 2020 | 2:15 PM
In the past years, next-generation sequencing has revolutionized the way testing is done in the field of clinical oncology research. Parallel testing of genomic markers in tissue biopsies as...
MAY 14, 2020 | 2:15 PM
In the past years, next-generation sequencing has revolutionized the way testing is done in the field of clinical oncology research. Parallel testing of genomic markers in tissue biopsies as...
MAY 12, 2020 | 9:00 AM
NEW DATE: Date: May 12, 2020 Time: 9:00am PDT, 12:00pm EDT...
MAY 08, 2020 | 8:00 AM
DATE: May 8, 2020 TIME: 8:00am PT, 11:00am ET Microsatellite instability (MSI) is the condition of genetic hypermutability that results from impaired DNA mismatch repair (MMR). Studies indic...
APR 29, 2020 | 6:00 AM
Background and aim: Multiplexing of biomarker panels by microsphere-based technologies are robust and cost-effective methods. The QuantiGene™ Plex Assay (ThermoFisher Scientific) platf...
APR 28, 2020 | 10:00 AM
DATE: April 28, 2020 TIME: 10:00am PT All cells release extracellular vesicles (EVs) that can carry molecular cargo to other cells to affect their function. EVs are promising as potential bi...